Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
· Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine · The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment · Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life Lund, Sweden — 10 May 2021 — Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes